Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

ProMIS Neurosciences Reports Increased R&D Expenses and Net Loss

Tipranks - Tipranks - Thu Aug 14, 2025

ProMIS Neurosciences Inc. ( (PMN) ) has released its Q2 earnings. Here is a breakdown of the information ProMIS Neurosciences Inc. presented to its investors.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

ProMIS Neurosciences Inc. is a biotechnology company focused on developing antibody therapies for neurodegenerative diseases, primarily targeting Alzheimer’s disease, multiple system atrophy, and amyotrophic lateral sclerosis. In its latest earnings report, ProMIS Neurosciences Inc. highlighted a significant increase in operating expenses, driven by research and development costs, leading to a net loss of $17.5 million for the first half of 2025. The company’s cash position decreased to $4.5 million from $13.3 million at the end of 2024, raising concerns about its liquidity. Despite the financial challenges, ProMIS continues to focus on advancing its pipeline of product candidates, including PMN310, PMN267, and PMN442, through clinical trials and strategic partnerships. Looking forward, ProMIS Neurosciences Inc. remains committed to securing additional funding to support its research and development activities, while navigating the uncertainties of the biotech market.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).